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8 Chapter 1
Huntington’s disease (HD) is an autosomal, dominant inherited neurodegenerative 
disorder, characterized by a triad of symptoms including motor abnormalities, 
behavioral symptoms and cognitive decline1. The prevalence of HD varies between 
by HD2. The mean age of disease onset is between 30 and 50 years of age with a disease 
duration of 17 to 20 years1.
In 1872, George Huntington (1850-1916) described the clinical features of, what 
is now called, Huntington’s disease. In his essay ‘On Chorea’, he already described 
the hereditary nature, midlife onset, and the clinical symptoms3. Roughly 100 years 
later, in 1983, the huntingtin gene was mapped to the short arm of chromosome 
4 which made linkage analysis possible4. Ten years later, in 1993, the mutation 
trinucleotide on chromosome 4 in the huntingtin gene and genetic testing became an 
option for individuals at risk5
point in life, however, it cannot be predicted at what age individuals start to develop 
symptoms6 7. 
Clinical symptoms and measurement tools 
 HD symptoms can be categorized in three domains: motor, cognitive, and behavioral. 
Motor symptoms are the most recognized signs of HD and typically a clinical diagnosis 
is determined based on the occurrence of motor symptoms1, 8. The most characteristic 
motor symptom is chorea, unwanted, jerky movements, but other motor symptoms 
such as dystonia, rigidity, hypokinesia and bradykinesia are also often present. The 
symptoms worsen over the course of the disease and will eventually interfere with 
daily activities, such as getting dressed and walking1
Rating Scale (UHDRS) was designed to rate the most common symptoms, including 
motor symptoms, and general functional capacity of daily living of HD expansion gene 
carriers (HDGEC)9. The motor part of the UHDRS is still the gold standard to rate 
motor abnormalities. This scale ranges from 0 to 124, with higher scores indicating 
indicate whether HDGECs have substantial motor symptoms; i.e. distinction between 
pre-motormanifest and motormanifest individuals. The UHDRS has a high inter-
rater reliability9. Recently, a force transducer, the Q-motor, was developed to be able 
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9Introduction
to even detect subtle changes in motor performance and was recently used in clinical 
trials10.
Cognitive decline is another major HD symptom and was already recognized 
by George Huntington3. The last decades, the cognitive component of HD has 
been extensively studied, this might partially be ascribed to the fact that cognitive 
deterioration embodies several cognitive domains which all can be measured with 
11. This is also the challenge to identify the natural course of cognitive 
that cognitive deterioration can occur before motor symptoms are present and simple 
psychomotor tasks seem to be sensitive in the period before motor symptoms become 
present11-13 whereas tasks of memory and executive functioning appear to become 
sensitive in the early HD stages12-14. Still the exact course of cognitive decline for each 
HD11
15 was designed to 
track cognitive decline in the early HD phase, i.e. clinically diagnosed HDGECs with 
still high functional capacity in daily living. However, considering the entire spectrum 
of the disease, no consensus exists which cognitive tasks should be used in which 
stage.
throughout the course of the disease16, 17. The most common behavioral symptoms are 
depressive mood, irritability and apathy17. Other symptoms such as hallucinations, 
in the pre-motormanifest stage18, 19 and will eventually be severely present in the 
late stage16. It seems that apathy is the only behavioral symptom which worsens as 
disease progresses, suggesting a neurodegenerative cause, and is negatively related 
to functional capacity16, 20. In addition, apathy and cognitive impairment are also 
result of working memory problems or executive dysfunction21. In HD it has been shown 
that apathy is associated with cognitive decline22.   Several rating scales have been used 
in HD to track the behavioral symptoms in HD but only a few are recommended to 
behavioral symptoms23
structured psychiatric interview, was develop for HD and is now commonly used to 
24. 
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to understand the relationship between HD symptoms and the underlying 
neurodegenerative process. Magnetic resonance imaging (MRI) technique was 
often used to map symptoms to structural and/or functional changes in the brain 
in HD25. These  studies showed that atrophy of the putamen is correlated to motor 
symptoms26,27 14, and that 
striatal atrophy already starts before symptoms become apparent19
unknown about the development of symptoms and the neurodegenerative process. 
symptoms. In a large European study about 85% received symptomatic treatment, 
the majority for depression28. Unfortunately, there is only low level of evidence on 
prescription is based on clinical practice29-31.  
Aims
developing apathy is still lacking in HD, the primary aim of this thesis was to gain 
This information is incredible useful to advice future clinical trials about their design 
if cognitive decline and/or apathy is targeted.
centers. In 2004, the European Huntington’s Disease Network (EHDN) launched 
the European, multicenter, observational REGISTRY study32. We aimed to evaluate 
between HDGECs and whether these groups are homogeneous by giving an overview 
of the participants’ characteristics at the largest REGISTRY HD center (chapter 2). 
Secondly, using the entire European REGISTRY cohort, we aimed to map the cognitive 
chapter 
3
between individuals taking medication targeting non-cognitive neuropsychiatric signs 
or/and tetrabenazine and non-users in HD (chapter 4). The following two chapters 
focus on apathy, we aimed to relate apathy to the neurodegenerative process in HD 
(chapter 5). In chapter 6, we evaluated whether HDGECs and their proxies agree 
on the degree of apathy by using a self-report questionnaire. General discussion of our 
chapter 7.
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Abstract
Background: REGISTRY is the largest European observational study of 
Netherlands is the largest recruiting site. 
Objective: The aim of this paper is to give an overview of the baseline characteristics 
Methods
and presence of motor signs. 
Results
second way of dividing the participants based on present or absent of motor signs, 
showed that 170 pre-motormanifest - and 317 motormanifest participants were 
enrolled. 
Conclusion
by full penetrance gene expansion carriers who have been clinically diagnosed with 
participants, disease onset was based on motor signs followed by psychiatric and 
cognitive signs. 
530433-L-sub01-bw-Baake
Processed on: 11-4-2019 PDF page: 17
17REGISTRY participants
Introduction
Huntington’s disease (HD) is a devastating neurodegenerative disease with 
in Western countries1, 2. It is characterized by a triad of symptoms: progressive 
motor abnormalities, behavioral signs and cognitive deterioration3. HD is caused 
by an unstable trinucleotide repeat expansion which codes for mutant huntingtin 
on chromosome 44. With the discovery of the expanded gene and its exact location4 
individuals who are at risk of developing this disorder can be tested for the expanded 
HD gene before any clinical signs become apparent. The fully penetrant nature with 
signs of HD during their normal life span5. Over a course of, on average, 15 years, 
signs will gradually worsen, severely debilitate the patient, resulting in premature 
death6. Currently, symptomatic treatment is available, but as yet no cure or disease 
into disease progression which in turn might identify underlying disease mechanisms. 
numbers of participants are needed to investigate the multimodal progression of HD, 
research relies heavily on international, multicenter studies, such as REGISTRY7, 
COHORT8, PREDICT-HD9 10. 
The REGISTRY study is a European, multicenter, observational study coordinated by 
the European Huntington’s Disease Network (EHDN)7. It was initiated in 2004 and 17 
European countries have recruited or are still recruiting asymptomatic, symptomatic, 
functioning are administered according to standard procedures and participants are 
sectional and longitudinal data.
participants enrolled, is the largest site in the REGISTRY followed by Madrid (Spain; 
497 participants) and Münster (Germany; 464 participants). In Europe, the REGISTRY 
sites are being closed one by one in the transition to the worldwide, observational 
Enroll-HD study (for more information see www.enroll-hd.org). The REGISTRY site 
REGISTRY participants at baseline visit. 
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population thoroughly provides particularly useful information for designing future 
clinical trials and their target population. This paper can give guidance as to which 
variables should be taken into account for recruiting participants in order to answer 
Methods
participate for various reasons: non-Dutch speaking, refusal, attended outpatient 
11, 
Riluzole12, HD-project13, PEP-HD14, Track-HD10 15, and local studies 
by the Department of Psychiatry16. Study assessments were administered by trained 
consent.
Participants
The REGISTRY study included asymptomatic and symptomatic HD expansion 
mutation carriers, at risk participants and healthy controls (either negatively tested 
th th, 2014 
(closing of REGISTRY), resulting in 589 baseline visits. In total, 42 participants were 
because of the low number of participants and the lack of consensus about whether 
intermediate gene carriers develop HD or HD-like phenotype17-19. This resulted in 547 
individuals taking part in the analysis, 60 of whom were controls.
20.
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Second, the cohort was divided on the basis of the presence of motor signs 
Scale (UHDRS)21
10. Other possible HD signs were not taken into 
consideration for this division. 
Variables
General demographic data consisted of date of birth, gender, handedness, ethnicity, 
education (total years), employment, and marital status (partner: yes/no). HD-
The personal history consisted of: age at onset, signs at onset, date of diagnosis and 
disease duration before baseline visit. These data were collected through an amnestic 
interview with participant and if possible partner/caregiver. Notably, age at onset 
independent of a clinical diagnosis. 
Clinical variables included items of the UHDRS: total motor score (TMS), total 
total correct score of the Stroop-Colour-Word-Interference test, the Symbol Digit 
Statistical analysis
None of the reported variables proved to be normally distributed. Therefore, 
1, 2, and 3.
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Results
length and presence of motor signs.
Cohort divided based on CAG length
penetrance participants (table 1). 
Demographic data
Age at baseline: 
55years) than the full penetrance group (median age: 46years) at time of baseline 
CAG smaller allele: 
(28/38). Seventeen participants of the full penetrance group had a smaller allele in 
the smaller allele (36/46) and was considered to be homozygote. 
  Reduced penetrance Full penetrance Control p-value 
Full cohort  Age in yearsa 55 (27-81) 46 (19-82) 49 (23-88) p < 0.05 
Gender: male/female 11/11 191/274 26/34 p > 0.05 
CAG smaller allelea 17 (15-28) 17 (9-36) 17 [49] (16-18)  p > 0.05 
CAG larger allelea 39 (36-39) 43 (40-59) 18 [49] (17-24)  p < 0.01 




Age at diagnosis in yearsa  
 
67 (36-81) 48 (23-82) NA p < 0.05b 
Age at symptoms first noted  
  by subject in yearsa  
53 (36-74) 45 [4] (20-78)  NA p = 0.05b 
Age at symptoms first noted  
  by family in yearsa  
53 (36-74) 44 [11] (20-75)  NA p < 0.05 b 
Rater’s estimate of age  
  at first symptoms in yearsa 
53 (36-73) 44 [11] (20-72)  NA p < 0.05 b 
Disease duration before  
  baseline visit in yearsa 
3 (0-17) 5 [11] (0-24)  NA p > 0.05 b 
Note: a median [number of missing data], (range); b testing only between reduced penetrance and full penetrance;  
NA: Not applicable; N: Number.  
Table 1: Division based on expanded CAG repeat length
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HD disease onset
In total, 335 participants were already diagnosed with HD at time of REGISTRY 
baseline visit: 9 reduced penetrance participants (41% of reduced penetrance group) 
and 317 full penetrance participants (68% of full penetrance group).
Age at diagnosis: 
age: 67) than the full penetrance group (median age: 48) at time of clinical HD 
 Within both the reduced penetrance and full penetrance 
groups, there was relative consensus between participant, family and professional 
 
 
onset started with motor signs in about 76%, cognitive decline in about 12 % and 
signs in about 49%, psychiatric changes in about 20%, cognitive decline in about 16% 
Years between disease onset and baseline visit: 
the reduced and full penetrance group regarding the years between rater’s estimate of 
Figure 1: First Huntington’s disease sign judged by rater, for reduced and full penetrance 
groups
Reduced penetrance Full penetrance
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Cohort divided based on presence of motor signs
In total, 170 pre-motormanifest (PMHD) - and 317 motormanifest (MHD) 
participants were included (table 2).
General characteristics
Age at baseline: 
Gender: 
of female participants (about 66% compared to 55% in MHD and 57% in control).
TFC: 
Pre-motormanifest with  
clinical diagnosis  
N=35 
Motormanifest with  
clinical diagnosis N=291 
p-value 
Age at diagnosisa 40 (28-65) 49 (23-82) p < 0.05 
Age at symptoms first noted by subjecta 38 (28-63) 46 [4] (20-78) p < 0.05 
Age symptoms first noted by familya 38 [2] (28-63) 45 [9] (20-75) p < 0.05 
Rater’s estimate of age at first symptomsa 38 [1] (28-63) 45 [10] (20-73) p < 0.05 
Disease durationa,b 3 [1] (0-11) 5 [10] (0-24) p < 0.05 
Note: a median in years [number of missing data], (range), b age at symptom onset by rater – age at baseline visit
Table 3: Huntington’s disease history for participants with clinical diagnosis
Pre-motormanifest Motormanifest Control p-value 
Age in years  38 (19-66) 51 (26-82) 49 (23-88) p < 0.05 
Gender: male / female 58 / 112 144 / 173  26 / 34  p = 0.05 
Employment: employed / unemployed 127 / 43 76 / 241 41 / 19 p < 0.05 
Marital status: partner / no partner 125 / 44 [1] 217 / 97 [3] 41 / 5 [14] p < 0.05 
Total Functional Capacity  13 (8-13) 9 [1] (0-13)  13 [13] (10-13)  p < 0.05 
Functional Assessment score  25 [3] (20-25)  22 [2] (0-25)  25 [14] (24-25)  p < 0.05 
Total Cognitive Score  291 [34] (189-407)  178 [123] (45-341)  298 [3] (189-439)  p < 0.05 
Total Behavioral Score  0 [31] (0-23)  4 [14] (0-26)  1 [42] (0-15)  p < 0.05 
Family history     
Affected parent: Mother/father/both 95 / 72 / 0 [3] 159 / 134 / 1 [25] 8 / 8 / 0 [44] p > 0.05b
Age at onset mother in years  45 [31] (25-71)  45 [54] (25-72)  50 [2] (44-57) † p > 0.05b 
Age at onset father in years  46 [17] (27-75)  48 [51] (20-91)  55 [1] (41-75) † p > 0.05b 
Note: a median [number of missing data], (range); b testing only between pre-motormanifest and motormanifest;
† only participants from a confirmed HD family. 
 
Table 2: Division based on motor symptoms
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22: 126 (40%) participants were in stage 1, 94 (29%) in stage 
participant’s baseline visit were missing.
HD disease onset for participants with clinical diagnosis
clinically diagnosed with HD based on either motor, cognitive, psychiatric or mixed 
symptoms: 35 PMHD (21% of all PMHD participants), and 291 MHD (92% of all MHD 
participants) (see table 3). 
Age at diagnosis: 
 There was a relative consensus between participants, families 
 Within both the PMHD group and MHD groups, there was consensus 
signs were psychiatric problems in 36%, followed by cognitive decline in 32%, motor 
cognitive decline in 15%, and mixed in the remaining 13%¹
1  Numbers are approximates
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Years between disease onset and baseline visit: 
Discussion
The present paper presents the descriptive data on demographics, clinical and HD-
majority of participants were clinically diagnosed with HD and were in an early or 
mid-stage of the disease. 
reduced penetrance range (about 5%) was comparable to the percentage described 
in the literature23, 24
in the reduced penetrance range. There are suggestions that these individuals have 
late HD onset25-27  with chorea as primary disease sign27, 28. This supports the notion 
29.
with HD prior to the REGISTRY visit with a relatively high functional capacity (e.g. 
that disease onset started most frequently with motor abnormalities. Nevertheless, 
for about one-third, disease onset started with cognitive and/or psychiatric signs as 
can precede motor signs by several years10, 30-35. This is even more stressed by the 
diagnosed with HD based on psychiatric and/or cognitive problems. This implies 
motormanifest and motormanifest participants and ignores all other HD symptoms.
Unfortunately, no consensus has been achieved on when psychiatric and/or 
a distinction between purely premanifest and manifest participants. More studies 
are, therefore, needed to investigate thoroughly the progression of psychiatric and 
cognitive problems throughout the disease and to be able to advise which instrument 
530433-L-sub01-bw-Baake
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based on motor abnormalities without reaching the TMS threshold. This suggests that 
certain items on the motor UHDRS are more associated with HD signs than others, 
research with purely premanifest HD, we can only advise that the clinical impression 
of the professional rater about whether any signs related to HD are present, should be 
taken into consideration. This could be implemented according to the newly proposed 
clinical diagnostic criteria which include and evaluate all HD signs36.
Interestingly, the clinically diagnosed PMHD participants were enrolled in 
REGISTRY after a shorter period between estimated disease onset and baseline visit 
problems are more devastating for patients and caregivers37, 38 and, therefore, they 
attend the outpatient clinic earlier. Moreover, patients who attend an outpatient clinic 
at a younger age and have regular follow-ups have a higher chance that HD signs will 
Surprisingly, the occurrence of psychiatric symptoms was relatively low in the 
39. One explanation 
could be that these patients are not recognized, under-diagnosed, referred directly to 
psychiatrists, or not willing to participate in studies.
participants who already experienced symptoms related to HD but who were still 
diagnosed participants, disease onset was based on motor symptoms followed by 
early HD patients, it is particularly interesting for future clinical trials with the focus 
on delaying disease onset and/or progression. 
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Abstract
Background: In Huntington’s disease (HD) cognitive decline can occur before 
the course of the disease and has a progressive nature over time, cognition can be 
cognitive decline over time is unknown.
Objective: The aim of this study is to quantify the progression of cognitive decline 
across all HD stages, from pre-motormanifest to advanced HD, and to investigate if 
Methods: In the European REGISTRY study 2,669 HD expansion gene carriers 
underwent annual cognitive assessment. General linear mixed models were used 
to model the cognitive decline for each cognitive task across all disease stages. 
length and age rather than disease stage. 
Results: 
throughout pre-motormanifest (close to estimated disease onset) participants and the 
subsequent motormanifest participants from stage 1 to stage 4. Performance on the 
pre-motormanifest groups: far and close to estimated disease onset. 
Conclusion: Cognitive performance already shows decline in pre-motormanifest 
HD gene expansion carriers and gradually worsens to late stage HD. HD gene 
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Introduction
Huntington’s disease (HD) is an autosomal dominant inherited, progressive 
gene on chromosome 41 and is characterized by motor and psychiatric symptoms, 
and cognitive decline. Typically, a formal clinical diagnosis of HD is based on the 
appearance of unequivocal motor signs2. The importance of psychiatric symptoms 
and cognitive decline has become more recognized and new guidelines have been 
proposed, which include these signs for clinical diagnosis3. Still, these signs are 
and should be taken into consideration for a clinical diagnosis3. 
In the last decade, there has been a growing interest in the cognitive decline and many 
studies have focused on this aspect in HD. Nevertheless, there have been relatively 
few longitudinal studies to date to track the progression of cognitive functioning, 
4-9 which can be attributed to the 
tasks administered, length of follow-up, sample size and characteristics of participant 
sensitive to particular stages of HD to track disease progression: simple psychomotor 
tasks have been shown to be particularly sensitive in the 5-10 years preceding motor 
symptoms onset10-13 whereas performance on tasks of memory and executive function 
appear to decline particularly around the time of clinical disease onset10, 11, 14, 15. It has 
also been demonstrated that simple psychomotor tasks are more sensitive to use in 
longitudinal studies than more complex tasks of executive function in pre-motor 
manifest and early HD4, 16, 17. Thus far studies of cognition in HD over time have been 
limited to the study of pre-motormanifest and/or early HD. To our knowledge no 
studies have longitudinally examined cognition across all separate disease stages 
with a large sample size, which is essential to fully understand the natural course of 
particularly useful for future clinical trials targeting cognition, in order to evaluate the 
18
brain atrophy15, 19 18, it is of 
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raise more awareness that certain individuals have a higher risk at developing early 
In 2004 the European Huntington’s Disease Network (EHDN) launched the 
observational REGISTRY study20, in which HD expansion gene carriers undergo 
annual assessment of motor function, cognition, behavior, and day-to-day functioning. 
opportunity to explore cognitive change across all HD stages. The aim of this study is 
to evaluate the progression of cognitive decline in HD throughout the disease stages, 
cognitive decline. The second aim is to assess whether the individual cognitive tasks 
Methods
Data was acquired from the European, multicenter, longitudinal, observational 
ethical approval before conducting the study and all participants gave written informed 
consent. Study assessments were administered by trained professionals and all data 
20.
Participants
38 and 50 (both inclusive) and visits of participants with age between 25 and 80 (both 
inclusive) at time of assessment were included in the analysis. Resulting in a total of 
2,669 participants for analysis with a mean of 3.7 annual visits, ranging from one to 
12 visits per participants (table 1).
indicating no substantial motor signs. This pre-motormanifest group was further 
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and colleagues21-24
25, using the total function capacity scale of the UHDRS.  
Assessments
of ±three months. The time window was not strictly enforced and it was possible 
to assess participants outside their time window or even miss annual visits without 
exclusion of the study. 
The REGISTRY cognitive battery consisted of the UHDRS’ cognitive tasks: Phonemic 
Stroop-Color-Word-Interference task: word reading, color naming and interference 
condition (total number correct within 45 seconds for each condition), and Symbol 
Digit Modalities task (total number correct in 90 seconds)26. In 2010, the Categorical 
27. 
On each task a higher numerical score indicates higher cognitive performance. These 
raw cognitive scores at each visit were used for the statistical analysis. 
Depression was assessed by means of the behavior assessment of the UHDRS26 or 
28.
Medication use was also recorded as part of the REGISTRY study; medications 
categories: benzodiazepine, antidepressant, antipsychotic, atypical antipsychotic, 
anticonvulsant, opioids, antiparkinsonian and others. 
 
Statistical analysis
an unequal number of visits and missing values29. Two models were designed to 
understand the progressive nature of cognitive decline in HD. 
disease stage was analyzed, adjusting for depressive mood, sex, years of education, 
medication use, study site and third order polynomial function of age. The results 
in rate of cognitive decline by disease stage. Per task it was analyzed if there was a 
important to note, as participants came in for testing over several years, it was 
common that participants progressed from one disease stage to the next. In order to 
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compare cognitive performance between disease stages participants were allowed to 
transfer into the next category of disease stage on a subsequent visit dates to maintain 
homogenous groups. 
The second model assessed change over time in performance on the cognitive tasks 
for depression, sex, years of education, medication use, and study site. Per task it 
lengths of 38 and 40 was compared for ages 30, 45, and 60.  
 Results
Cognitive task performance based on disease stage
declined most rapidly. More precisely, performance on the Stroop Word Test decreased 
 
 PreA PreB Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 
Gender (m/f) baseline visita 118 / 219 108 / 143* 423 / 365* 357 / 386 234 / 239 25 / 46 1 / 5 
Gender (m/f) last visita 78/162 69/115* 250/238* 352/316 384/399 120/150 13/23 
Number of visitsb 3.8 (1-8) 4.2 (1-12) 3.8 (1-10) 3.6 (1-9) 3.1 (1-9) 2.6 (1-7) 2.0 (1-2) 
Age (years)c 36 (9)* 42 (10)* 48 (11)* 52 (11)* 54 (11)* 55 (10) 58 (11) 
Education (years)c 13 (4) 13 (4)* 12 (4)* 11 (4)* 11 (3)* 10 (4) 11 (4) 
CAG lengthc 41 (2.0)* 44 (2.6)* 44 (2.8) 44 (2.8) 44 (2.6) 44 (2.7) 43 (3.7) 
PreA: pre-motormanifest A; PreB: pre-motormanifest B 
atotal number; significant difference between the groups marked with * 
bParticipants were grouped based on baseline characteristics; mean (range) 
cmean (standard deviation); significant difference between the groups marked with * 
Table 1: Group characteristics
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In contrast to the results of the Stroop Word Test, no pronounced and rapid decline 
The results of the other administered tasks were somewhere in between the results 
Test (table 2) but the slope for decline was less steep for the Stroop Color Test than for 
Interference Test and the Symbol Digit Modalities Test was found between all disease 
decline was less pronounced than for the Stroop Interference and the Symbol Digit 
Modalities test. 
 N PreA – PreB PreB – Stg1 Stg1 – Stg2 Stg2 – Stg3 Stg3 – Stg4 Stg4 – Stg5 
Phonemic verbal fluencya 2548 1.66 (0.55) 4.03 (0.40)* 3.16 (0.26)* 3.56 (0.25)* 2.46 (0.42)* 0.39 (1.40) 
Stroop Colora 2554 5.08 (0.70)* 4.56 (0.51)* 6.40 (0.33)* 6.56 (0.32)* 5.20 (0.53)* 5.25 (1.62)  
Stroop Worda 2526 5.35 (0.97)* 7.00 (0.71)* 8.34 (0.45)* 9.60 (0.42)* 8.41 (0.71)* 7.49 (2.21)  
Stroop Interferencea 2540 3.50 (0.52)* 3.81 (0.39)* 4.10 (0.25)* 3.90 (0.24)* 3.78 (0.42)* 1.57 (1.37) 
Symbol Digit Modalities Testa 2521 3.49 (0.49)* 4.59 (0.36)* 4.02 (0.23)* 4.29 (0.22)* 2.76 (0.40)* 1.71 (1.53) 
Categorical Fluencya 1410 2.18 (0.51)* 3.50 (0.42)* 2.27 (0.27)* 2.42 (0.25)* 2.02 (0.42)* 0.69 (1.44) 
PreA: pre-motormanifst A; PreB: pre-motormanifest B; Stg1: disease stage 1; Stg2: disease stage 2; Stg3: disease stage 3; Stg4: disease stage 4;  
Stg5: disease stage 5 
 a Estimate (SE); * sig < 0.008. 
per cognitive task
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Cognitive task performance based on CAG length and age
described model in the methods section, and these results were used to compare 
between the cognitive performance is the same as well. 
Table 3: Comparing CAG length 42 with 44 on cognitive task performance based on 
longitudinal model
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together than for the Stroop Word Test. The results for all cognitive tasks are presented 
Discussion
This current study evaluates the progression of cognitive decline in HD, from 
pre-motormanifest to late stage. Performance on the REGISTRY cognitive battery 
the disease process and even proceeds overt motor signs8, 10-12
of the cognitive tasks, taking into consideration the clinical relevance of decline, we 
demonstrated that the Stroop Word and Stroop Color Test are the most sensitive of 
Test are sensitive in pre-motormanifest8 and early HD30. We have now demonstrated 
that this remains so over the disease course and that these tasks remain sensitive in 
later stages of HD. These results are in line with suggestions of previous studies that 
simple psychomotor tasks are the most appropriate to use in longitudinal research in 
HD4,16,17. This information is particularly useful for clinical trials as cognition is seen 
as a key target for symptomatic treatment. 
It has been argued that because the Stroop Word test and Stroop Color test have 
high linguistic demands they should not be included in test batteries for HD as clinical 
trials rely heavily on multicenter research across several countries31. Nevertheless, the 
with correcting for study site we conclude that these tasks are sensitive in tracking 
we would strongly recommend to include the Stroop Word and Stroop Color test in 
disease stage 5; i.e. none of the tasks discriminated between these two stages. This 
suitable cognitive task for late stage HD. It is a challenge to administer cognitive tasks 
in this patient group because many patients are not able to write or speak anymore.
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inter rater reliability of this scale is unknown, which could be challenging for multi-
earlier disease onset and faster disease progression32. Therefore, we plotted cognitive 
objective and therefore more suitable variables than disease stage to investigate the 
natural course of cognitive decline in HD. This approach revealed that participants 
8 in the pre-
disease progression32, including cognitive decline. More precisely, the relationship 
of psychomotor function, i.e. Stroop Color and Stroop Word Test, rather than tasks 
17, 33
striatum starts to degenerate early in the course of HD34 it seems logical that functions 
relying on the involvement of the nucleus caudate decline early on and are progressive 
in HD, such as psychomotor speed.
capture cognitive decline in HD but rather to map disease progression of several 
also moderate to advanced HD patients the cognitive battery was rather short. We 
acknowledge that other studies purely focusing on cognition in HD have utilized a 
wider range of cognitive tasks31. However, given the large sample size available, 
representing all stages of disease across multiple sites and countries, our results 
provide a valuable contribute to the understanding of cognitive decline in HD.
available in the REGISTRY database. Thus, we were not able to compare the cognitive 
Therefore, we also evaluated if the cognitive decline was clinical relevant: for example 
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evaluated a decline of on average three points as not clinically relevant and concluded 
and worsens with age. The Stroop Word and Stroop color test are sensitive in tracking 
psychomotor speed in HD in all stages and we recommend inclusion of these tasks in 
cognitive batteries for clinical trials. 
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Abstract
Background: In Huntington’s disease (HD), cognitive decline starts early 
performance in HD. Medication treating non-cognitive neuropsychiatric disturbances 
cognition, are often prescribed in HD patients. 
Objective: 
users and non-users of these drugs at HD clinics throughout Europe. 
Methods: 
cognitive assessment and recorded medication use at their baseline visit. Participants 
were grouped according to disease stage and medication use: i.e. benzodiazepines, 
selective serotonin reuptake inhibitor (SSRI) antidepressants, antipsychotics, atypical 
antipsychotics and tetrabenazine. Univariate general linear model analysis was 
conducted. 
Results: Medication use was common in the REGISTRY cohort. In total 42% of 
used increased from 12% in the pre-motormanifest stage to 81% in the advanced 
Test was found in the early HD stages. 
Conclusions: 
tetrabenazine on cognitive performance was found. Only the use of antipsychotics had 
when designing clinical trials with cognition as clinical endpoint. 
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Introduction
Huntington’s disease (HD) is an autosomal dominant inherited, progressive 
on chromosome 41. HD is characterized by a triad of symptoms: motor abnormalities, 
behavioral signs and cognitive deterioration2
gene is known, individuals at risk can be tested for the expanded HD gene before any 
symptoms or signs appear. 
Motor abnormalities are the most characteristic signs of HD, but gene-expansion 
carriers and caregivers perceive cognitive decline and behavioral signs to be the 
most burdensome3, 4. These can precede motor signs by several years5-13
decline starts early and continues as the disease progresses, cognition is recognized as 
a potential endpoint in clinical trials. Nowadays, a broad range of cognitive domains 
is evaluated in almost all clinical trials14, including psychomotor speed which starts to 
slow down early on and continues to worsen throughout the later HD stages15, 16. It is 
in order to evaluate whether potential interventions could stop or slow down cognitive 
decline in HD.
Many HD gene expansion carriers take psychotropic medication for behavioral and 
depressive signs; i.e. medication targeting non-cognitive neuropsychiatric signs2, 17. 
received symptomatic treatment18. Unfortunately, there is only low level of evidence 
based on clinical experience19, 20. Depression is common in HD and is often treated with 
serotonin-norepinephrine reuptake inhibitors (SNRIs). There is some evidence that 
21
are often treated with benzodiazepines20
cognitive performance in HD is not well documented. We do know from other studies 
that the higher the intake of benzodiazepines the greater risk of cognitive impairment 
and in the elderly population it is related to a higher risk of dementia22, 23
study it was shown that also the use of antipsychotics is common in HD and some 
24. In another study it was found that HD patients 
using antipsychotic medication (classical and atypical) or tetrabenazine had a faster 
disease progression25
the use of these types of medication have an impact on cognitive performance on HD. 
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many clinical trials individuals are not allowed to take any of these drugs because it 
Therefore, the aim of this observational, explorative study is to investigate whether 
using medication targeting non-cognitive neuropsychiatric signs or tetrabenazine 
compared to non-users in a clinical HD population. We expect that the SSRI group 
expect that users display a more impaired cognitive performance. This is evaluated in 
a large HD population seen at several specialized HD clinics throughout Europe, no 
medication use was adapted for this study.
Methods
Participants
REGISTRY is a European, multicenter, longitudinal, observation study, facilitated 
completed the cognitive assessment at baseline. Participants without any motor signs, 
Rating Scale (UHDRS)14, were considered pre-motormanifest. These participants 
26-29 and split at 
were further divided into disease stages based on total functional capacity scale30. The 
last two disease stages were merged into one due to the small number of participants 
in these two groups, stages 4 and 5. Ethical approval was obtained for all sites and 
all participants gave written informed consent. The study was conducted by trained 
et al.31.
Assessments
HD gene expansion carriers were assessed for day-to-day functioning, motor, 
Rating Scale (UHDRS)14 was used to evaluate cognitive performance: letter verbal 
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Word-Interference Test: word-reading, color-naming and interference condition 
(total number correct for each condition in 45 seconds; here the colors are red, blue 
and green), and the Symbol Digit Modalities Test (total number correct in 90 seconds).
participants were grouped as follows: taking benzodiazepines, selective serotonin 
reuptake inhibitor (SSRI) antidepressants, antipsychotics, atypical antipsychotics or 
appendix 1. Participants were allowed to take other medication prescribed for other 
conditions such as hypertension. 
 
Statistical analysis
appropriate, a chi-square test was used. 













Agea 34 (8) 42 (10) 47 (11) 51 (12) 53 (11) 54 (11) 
CAG repeat lengtha 42 (2) 44 (3) 44 (3) 44 (3) 44 (3) 45 (4) 
Years of educationa 13 (3) 13 (7) 12 (5) 11 (4) 11 (6) 10 (3) 
Sex (Male/Female)b 96/187 104/135 384/328 304/315 189/189 20/38 
PreA: pre-motormanifest A; PreB: pre-motormanifest B 
aMean (standard deviation) 
bTotal number 
Table 1: Group characteristics
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In total 58% of the participants did not use any medication. If disease stage was 
considered, the percentage of participants not taking medication gradually declined 
users were already on medication for at least 2 months with stable doses.
users in group stage 2 and stage 3 scored on average lower than then non-users 
benzodiazepines, SSRI antidepressants, atypical antipsychotics or tetrabenazine had 
Discussion
This study shows that about half of the HD-REGISTRY population used medication 
targeting non-cognitive neuropsychiatric disturbances and/or tetrabenazine. The 
percentage of HD gene carriers taking these medications increased from pre-
motormanifest to the advanced HD. The most logical explanation for this increase 













No medicationa 251 (88%) 202 (85%) 463 (65%) 283 (46%) 113 (30%) 11 (19%) 
Benzodiazepinesa 6 (2%) 5 (2%) 23 (3%) 29 (4%) 9 (2%) 2 (3%) 
SSRIa 16 (6%) 24 (10%) 84 (12%) 78 (13%) 43 (12%) 3 (5%) 
Antipsychoticsa 1 (<1%)  8 (1) 10 (2%) 14 (4%)  
Atypical antipsychoticsa 1 (<1%)  62 (9%) 86 (14%) 66 (17%) 13 (23%) 
Tetrabenazinea  1 (1%) 6 (1%) 13 (2%) 9 (2%) 1 (2%) 
Mixa 8 (3%) 7 (2%) 66 (9%) 120 (19%) 124 (33%) 28 (48%) 
PreA: pre-motormanifest A; PreB: pre-motormanifest B 
aTotal number (%) 
Table 2: Total number of participants taking medications
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which need to be managed with medication. In addition, the pre-motormanifest 
20. Throughout disease progression symptoms 
become more severe, global functioning decreases and medication treatment becomes 
useful, supported by adjunctive therapies, to manage all symptoms32. Polypharmacy is 
common in HD due to the complexity of the disease and several symptoms which need 
to be addressed20 which is supported by our results that about 40% of all medication 
Figure 1: Performance on the Stroop Word Test per disease stage and medication group
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stage of the disease to ensure the highest quality of life for the HD gene carriers. With 
antipsychotic medication if cognition is an important outcome measure of a clinical 
trial. 
Secondly, our study showed that the use of benzodiazepine, SSRI antidepressant, 
on cognition is in line with the 80 week open label study of tetrabenazine in HD in 
which cognitive decline resembled the natural deterioration in HD33. Regarding future 
clinical trials targeting cognition in HD, we advise that the use of benzodiazepine, 
SSRI antidepressant, atypical antipsychotic or tetrabenazine should be allowed if 
participants are on a stable dose and if there is no suggestion that these medications 
make it easier to recruit participants for clinical trials as many HD gene carriers use 
these medications. It also allows to test an investigational drug in a cohort which more 
population and improves the chance to have a successful phase III study.
One of the limitations of this study is that we grouped together the most commonly 
In addition, we chose to group the medication based on relatively broad categorization 
as used by the Dutch regulatory agency. These categorization is based on broad 
of the acting agent. The reason for this is that most studies are based on animal or cell 
or even in the diseased human brain. It might be of interest for future studies to explore 
medication, not at the exact doses taken, although we do know that the majority was 
on a stable dose. In addition, participants were allowed to take co-medications, such 
On a positive note, the REGISTRY database provides an opportunity to look at real-
the early HD stages, whereas benzodiazepines, SSRIs, atypical antipsychotics and 
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Abstract
Background: Huntington’s disease (HD) is characterized by motor and behavioral 
symptoms, and cognitive decline. HD gene carriers and their caregivers report the 
common behavioral symptom of HD and is related to clinical measures of disease 
progression, like functional capacity. However, it is unknown whether apathy is 
directly related to the neurodegenerative processes in HD.
Objective: The aim is to investigate whether an association between atrophy of 
subcortical structures and apathy is present in HD, at baseline and after 2 years 
follow-up. 
Method: Volumes of 7 subcortical structures were measured using structural 
baseline, logistic regression was used to evaluate whether volumes of subcortical 
used to assess whether subcortical atrophy was associated with the degree of apathy 
at baseline and with an increase in severity of apathy over time.   
Results: 
of the presence of apathy in HD gene carriers, but none of the subcortical structures 
was associated with the degree of apathy. Over time, no association between atrophy 
of any subcortical structures and change in degree of apathy was found.
Conclusion: The presence of apathy is associated with atrophy of the thalamus 
in HD, suggesting that apathy has an underlying neural cause and might explain the 
high incidence of apathy in HD. However, no association was found between atrophy 
of these subcortical structures and increase in severity of apathy over a 2-year time 
period. 
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Introduction
Huntington’s disease (HD) is an autosomal dominant inherited, progressive 
neurodegenerative disorder, characterized by motor and behavioral symptoms, 
and cognitive decline1
highest burden reported by HD gene carriers and caregivers are the cognitive and 
behavioral symptoms2
3, 4. The most 
common behavioral symptoms are depressive mood, irritability, and apathy with a 
measurement tools used, and disease stage4. Of these symptoms, apathy is the only 
behavioral symptom that worsens as the disease progresses3, 5, 6. In general, apathy 
reduced goal oriented behavior, emotions, and cognitions”7
on psychosocial functioning, including relationships with partners and caregivers, e.g. 
apathetic individuals need to be prompted into starting daily tasks such as getting 
dressed8, 9.
In HD, apathy can develop early in the course of the disease3, 10 and can even be 
mildly present in pre-motormanifest gene carriers5, 11. Over the course of the disease, 
apathy worsens and eventually apathy is severely present in almost all late stage 
gene carriers3. In addition, apathy itself is negatively related to functional capacity, 
cognitive performance and motor impairment in HD12. To better understand this 
behavioral symptom it is of interest to investigate the presence, severity and course 
of apathy in relation to the structural neurodegenerative processes that occur in HD.
Previous research has shown that apathy is caused by an interruption of the 
13
the brain14, 15. This circuit functionally connects the anterior cingulate cortex, nucleus 
accumbens, olfactory tubercle, and the ventromedial parts of the caudate nucleus and 
ventral putamen15. In subcortical neurodegenerative diseases, such as Parkinson’s 
disease and progressive supranuclear palsy, there is evidence that atrophy of the 
basal ganglia results in apathy14, 16. One study showed that the nucleus accumbens, 
an important subcortical structure of the reward circuit17, is associated with apathy in 
Parkinson’s disease18. In HD, it is not clear whether the same or other structures are 
related to apathy. Since degeneration of the basal ganglia is a key feature of HD, it is 
likely that these structures are associated with the occurrence of apathy in HD.
Dependent on disease stage, grey matter atrophy can be found in almost all grey 
matter structures in HD6, 19, 20. The caudate nucleus is known to already show atrophy 
in pre-motor manifest HD gene carriers, far from estimated disease onset19, 21-23 and 
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also shows the highest rate of degeneration as the disease progresses15, 24-26, followed by 
the putamen11, 27-29. Volume loss of the nucleus accumbens is already present in the late 
pre-motormanifest stage30. It is expected that volume loss of subcortical structures 
of the anterior cingulate circuit will be related to the development of apathy in HD 
patients. 
Given the progressive nature of apathy and its close relationship with measures of 
disease progression such as a decrease of cognitive function31, and general functioning3, 
it is possible that apathy is related to a neurodegenerative progress of subcortical 
gray matter in HD. Therefore, the aim of this study is to investigate the relationship 
between volume loss of subcortical structures and apathy in HD and whether there 
are changes over time. 
Methods
Participants
a total of 171 HD gene carriers (91 pre-motormanifest HD gene carriers and 80 
motormanifest HD gene carriers) completed the baseline and follow-up visit after 24 
motormanifest group was further divided into ‘far from estimated disease onset’ 
32. The group consisting 
33
gave written informed consent prior study procedures. The study was conducted by 
trained professionals and all data was monitored, for a full description of the study, 
see Tabrizi et al.11. 
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Clinical measures
In addition to the collection of general sociodemographic and clinical characteristics, 
and frequency on a 5-point scale34. Severity score ranges from absent (score 0) to 
severe (score 4) and frequency score ranges from absent (score 0) to every day/all day 
(score 4). In this study, both the product score of severity and frequency of the apathy 
item, and only the severity score of the apathy item were used. 
In this study two concepts were evaluated: the degree of apathy and the presence of 
apathy (i.e. apathy is or is not present). To indicate the degree of apathy the product 
on only the severity apathy item was used. 
MRI acquisition and processing
up on a Siemens or Philips whole body scanner depending on study site. 3D-T1-weighted 
image volumes were acquired with the following imaging parameters, as reported in 
the supplementary appendix in Tabrizi et al.11
(Siemens)/24cm (Philips), matrix size 256×256 (Siemens)/224×224 (Philips), 208 
(Siemens)/164 (Philips), sagittal slices to cover the entire brain with a slice thickness 
of 1.0mm with no gap between slices.
35 was used for analyzing the structural T1-weighted images. Combined left 
and right volumes of the following seven subcortical brain regions were measured: 
nucleus accumbens, amygdala, caudate nucleus, hippocampus, pallidum, putamen, 
36. 
37
registered to the Montreal Neurological Institute (MNI) 152-space standard image, 
using linear registration with 12 degrees of freedom38. Then, segmentation of the 
seven subcortical regions was carried out and volumes for each region were calculated. 
Visual inspection was performed during the registration and segmentation steps. The 
volumes of these brain regions were corrected for estimated brain tissue volume, 
39. 
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Statistics
apathy scores: SSRIs, SNRIs, anti-psychotics, tricyclic antidepressants, buproprion, 
benzodiazepines, anti-epileptic, and tetrabenazine. One binary variable was created to 
indicate whether any of these medications were taken during the visit. We acknowledge 
on apathy. Therefore, each model was run with and without the variable medication 
to identify the impact of medication on apathy. 
product score was developed to investigate a possible association between volume 
between each subcortical brain structure and presence of apathy (i.e. apathetic 
(severity*frequency) was added as additional covariate. 
To explore the relationship between apathy and volume loss over time, delta scores 
for apathy product score and delta scores for each brain structure were calculated to 
model was designed to examine an association between delta score of apathy and 
model was run once for all participants and once only for participants with an increase 
in the degree of apathy over time.
executed tests). 
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Results
were seen 23 months (SD: 1 month) after baseline visit. 
Baseline visit
Throughout the consecutive disease stages the percentage of participants with 
2 HD group, see table 1. 
The linear regression model did not reveal any association between volume of the 
separate subcortical brain structures and the apathy product score. The results did 
not change by adding the covariate depressive mood or by excluding the covariate 
medication use in the original model. 
associations were found, and the results did not change when the covariate depressive 
mood was added. If medication use was excluded as a covariate in our original model, 











Gender: m/f a 25/27 18/21 19/31 17/13 p = 0.43 
Age in years (SD) at baselineb 46 (9) 46 (9) 51 (10) 56 (8) p < 0.001 
CAG lengthb 42 (2) 44 (2) 44 (4) 43 (2) p = 0.001 
Medication use at baseline (%)a 9 (17%) 9 (23%) 18 (36%) 26 (87%) p < 0.001 
Medication use at baseline and FU (%)a 8 (15%) 9 (23%) 18 (36%) 25 (83%) p < 0.001 
Apathy at baseline (%)a 6 (12%) 6 (15%) 12 (24%) 15 (50%) p = 0.001 
Apathy at FU (%)a 5 (9%) 10 (25%) 18 (36%) 21 (70%) P < 0.001 
Months between visitsb 23 (1) 23 (1) 24 (1) 24 (1) p = 0.33 
Subgroups are created on baseline characteristics: PreA: pre-motormanifest A; PreB: pre-motormanifest B;  
HD1: motormanifest stage 1; HD2: motormanifest stage 2; FU: follow-up visit;  
p-value for main comparison, no post-hoc results are displayed 
atotal number 
bmean (standard deviation) 
Table 1: Group characteristics
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Follow-up
Overall, the percentage of apathetic participants increased over a time period of 
2 years, see table 1. When comparing the apathy product score at baseline with the 
apathy product score at follow-up for 16% of the participants apathy product score 
decreased by at least one point. Of 53% of the participants the apathy severity score 
stayed exactly the same and for 31% of the participants the apathy severity score 
increased by at least one point. 
None of the volumes of the subcortical brain structures were associated with change 
in the apathy product score between the two assessments; removing the covariate 
with increase of the apathy product score included in the analysis did not show other 
results, data not shown.
Figure 1: Probability of being apathetic based on volume of the thalamus
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Discussion
This study investigated the relationship between atrophy of subcortical brain 
structures and apathy in HD gene carriers at baseline and after 2 years follow-up. 
Cross-sectional analyses at baseline revealed that only atrophy of the thalamus was 
associated with the presence of apathy in HD, but no association between atrophy 
of the subcortical brain structures and the degree of apathy at baseline or over time 
basal ganglia circuit is involved in occurrence of apathy in HD, i.e. disruption of the 
circuit at the level of the thalamus is related to apathy. However, solely association 
circuits. Since disruption of the anterior cingulate circuit was associated with apathy 
in other neurodegenerative diseases13, 14, 16, 40, it is most likely that this circuit is also 
involved in the occurrence of apathy in HD. However, with only one structure being 
associated with apathy in our study, there is no conclusive evidence that the presence 
associations between apathy and atrophy of subcortical structures in HD. This is in 
other neurodegenerative disease14, 16, 18 and that degeneration of subcortical structures 
is prominently present in HD19, 22, 30, 41. However, we have neglected a possible 
disease and the cortex degenerates in the early HD stages11, 42. In these early stages 
apathy also drastically increases3 which is also supported by our results. This leads 
us to speculate that the underlying neural cause of apathy might not only be ascribed 
to atrophy of subcortical brain structures, but might also be associated with atrophy 
between the cortex and apathy in HD. In addition, it might be useful to explore other 
measurement tools for neural dysfunction, such as structural integrity or dopamine 
binding rather than volume reduction, to assess the relationship between apathy and 
neurodegenerative process in HD.
In the cross-sectional analysis we only found an association between the presence of 
apathy and volume reduction of the thalamus but not between the degree of apathy and 
volume reduction of any subcortical brain structure. To measure the degree of apathy 
as was done previously11. However, the product score bares some degree of uncertainty 
in what exactly is measured, it is unknown whether a high product score is a result of a 
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clinical presentations may have the same product score, e.g. someone with chronically 
mild apathy may have the same score as someone with occasionally severe apathy. In 
our opinion, these cases are not equal; hypothesis is that it is more likely that severity 
HD. McNally et al.43
using the product score might statistically not be appropriate as it is not a ratio scale. 
atrophy of the subcortical brain structures and change in the severity of apathy. In 
our cohort, apathy was already present in the early stages and the number of apathetic 
HD gene carriers increased. Over a time period of 2 years, in 31% of the HD gene 
carriers apathy scores worsened, while in 16% of the HD gene carriers apathy scores 
that apathy worsens over time in HD2, 3, to our knowledge only one other study 
found that over a time period of 2 years some apathetic individuals improved44
possible explanation might be that apathy itself is related to depression and the use 
of psychotropic medication; successful treatment of depression and/or use of other 
45
statistical model was adjusted for medication use. We acknowledge that by creating 
needed to investigate whether medication itself triggers apathy or whether apathetic 
HD gene carriers are more likely to use certain medication, which is important for 
results, we can only conclude that the severity in apathy does not drastically increase 
over a time period of 2 years in the pre-motormanifest and early stage of the disease, 
for the majority of individuals the apathy score stayed the same. The time period 
manifest and early HD population considering that disease duration is 17-20 years1. 
This is supported by Thompson et al.’s study3 in which more increase in apathy was 
found over a longer time period of on average 5 years and more advanced HD gene 
carriers.  
In conclusion, apathy is present in early stages of HD and is associated with atrophy 
of the thalamus in HD gene carriers, suggesting that occurrence of apathy has an 
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longer time period in more advanced stages and to evaluate the possible association 
between apathy and cortical atrophy in HD.
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Abstract
Huntington’s disease (HD) is characterized by motor and behavioral symptoms, 
related to disease progression. It has been suggested that HD gene expansion carriers 
are unaware of signs and symptoms of the disease, which might also account for their 
awareness of their own level of apathy. Therefore, the aim is to investigate the level of 
agreement on the degree of apathy severity between HD gene expansion carriers and 
their proxies using a self-report questionnaire. In total 109 REGISTRY participants 
(31 pre-motormanifest, 49 early motormanifest, and 29 late motormanifest) and their 
was used to assess whether HD gene expansion carriers and their proxies agreed on 
to late motormanifest stage. Pre-motormanifest HD gene expansion carriers scored 
were found between all motormanifest HD gene expansion carriers and their proxies. 
carriers can adequately assess their level of apathy on a self-report questionnaire. Our 
results even suggest that slight changes in the degree of apathy in pre-motormanifest 
HD gene expansion carriers remain unnoticed by their proxies. 
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Introduction
Huntington’s disease (HD) is an autosomal dominant inherited, progressive 
neurodegenerative disorder caused by an expanded trinucleotide expansion which 
codes for mutant huntingtin on chromosome 41. HD is clinically characterized by 
a triad of symptoms: motor abnormalities, behavioural symptoms, and cognitive 
deterioration2. The formal clinical diagnosis of HD is typically based on the appearance 
of unequivocal motor signs even though behavioural signs and cognitive decline often 
occur before motor sings are present2, 3
of the huntingtin gene, individuals at risk can be tested for the expanded HD gene 
before any signs and symptoms become apparent. New guidelines have agreed that 
clinical diagnosis can be made solely on behavioural and/or cognitive signs4. 
The behavioural symptoms in HD are diverse5, 6; the most common behavioural 
symptoms are depressed mood, irritability, and apathy with a prevalence varying from 
6. 
diminished goal directed behaviour, cognition, and emotion’7 -  is the only behavioural 
symptom which is closely related to disease progression in HD5. Therefore, it is 
suggested that apathy is caused by the neurodegenerative process in HD and could 
be seen as a marker of disease progression8. In HD, apathy is also associated with 
cognitive dysfunction and the use of psychotropic medication9. In their review of 
rating scales for behavioural symptoms in HD, Mestre et al.10 discuss three scales for 
assessing apathy in HD. Several studies11-13
14
reviewers mention a possible lack of insight by HD patients and they therefore favour 
Previous studies have shown that HD patients can be unaware of the signs and 
symptoms of the disease, including behavioural symptoms15, 16. The degree of impaired 
awareness of their own disability (anosognosia) varies dependent on symptom and 
its severity, cognitive function, and disease stage16. In clinical trials, a proxy is often 
asked to rate behavioural symptoms to avoid the risk of unawareness in HD gene 
expansion carriers (HDGECs). However, since it is not always possible to include 
HDGECs together with a reliable proxy only, it is of great relevance to evaluate 
whether HDGECs themselves are capable to adequately rate the severity of apathy 
using a self-report questionnaire. 
So far, only two studies have been conducted to investigate the level of agreement 
between HDGECs and their proxies in rating severity of apathy using a self-report 
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proxies11
between pre-manifest and manifest HDGECs and their proxies17
18, and on face value, the two questionnaires are comparable, although there 
10
HDGECs, we have conducted an additional study to evaluate whether HDGECs are 
less aware of their apathy severity than their proxies. 
Methods
Participants
The REGISTRY study19 is a European, multicentre, longitudinal, observational 
informed consent. In total 109 (31 pre-motormanifest, 49 early motormanifest, and 
29 late motormanifest) HDGECs and their proxies completed the Registry battery and 
HDGECs with a total motor score (TMS) of 
Rating Scale (UHDRS)20
with obvious HD motor signs. This motormanifest group was further divided into 
early motormanifest and late motormanifest according to disease stage based on the 
21
motormanifest and stage 3 and 4 were considered late motormanifest. No participants 
of stage 5 participated in this study. 
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the care professional/investigator; in this study the patient and proxy version were 
14. The 
HDGECs and proxies were independently of each other asked to rate to which degree 




was created to indicate whether the HDGEC used any of this medication. To evaluate 
and late motormanifest) on the severity of apathy, an analysis of covariance was 
carried out with medication use  and age entered as a covariate. The Wilcoxon signed-




showed that the pre-motormanifest group scored on average 10 points lower on the 
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score when the total group of HDGECs was compared with the rating of their proxies 
the pre-motormanifest HDGECs rated themselves as being more apathetic than their 
motormanifest HDGECs group rated apathy on 3 items one point higher than the 
Characteristics Pre-motormanifest  
(N=31) 
Early motormanifest  
(N=49) 
Late motormanifest  
(N=29) 
p-value 
 Mean SD Mean SD Mean SD  
Age in yearsb 38 9 54 11 57 11 p<0.01a,b 




Median Interquartile  
range 
 
CAG larger length 43 3 43 3 43 2 p=0.33 
Total motor score 1 2 22 23 52 22 p<0.01a,b,c 
SD: Standard deviation 
asignificant difference between pre-motormanifest and early motormanifest 
bsignificant difference between pre-motormanifest and late motormanifest 






























Table 1: Group characteristics
Figure 1: Patient and proxy Apathy Evaluation Scale (AES) score
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Discussion
In our cohort, apathy severity increased overall as the disease progressed throughout 
the clinically manifest stages. More precisely, the pre-motormanifest and early 
progression and that apathy is a common behavioural symptom in the advanced 
disease stage5
entire HDGEC cohort was compared with the score of their proxies, indicating an 
agreement on the severity of apathy between HDGECs and their proxies. However, 
motormanifest HDGECs experienced a higher level of apathy than was noticed by 
17 study that the apathy 
pre-motormanifest HDGECs tend to rate themselves as being more apathetic than 
motormanifest groups: Mason et al. reported that early disease patients also tend to 
rate themselves as more apathetic, whereas in late stage disease the proxies scored 
The other study that compared the self-reported with the caregiver assessment found 
that the proxies rated apathy as more severe than the HDGECs.11 However, in this study 
population was divided according to their cognitive ability: the agreement between 
HDGECs with good cognitive abilities and their proxies was high and this agreement 
dropped as cognitive abilities declined. Since HDGEC with better cognitive function 
is related to early disease stage, this group is comparable to the early motormanifest 
HDGEC group in our study, in which we have also found that HDGECs and proxies 
in the late motormanifest group with assumed declined cognitive abilities. 
early stage of the disease and the proxies have equal awareness of apathy severity. 
However, the pre-motormanifest HDGEC experience more apathy than is noticed by 
motormanifest HDGECs for the development of signs of the disease; the knowledge 
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are very subtle3, 22 and it might be a more internal feeling of which the proxies are 
not aware. This is supported by that most discrepancies are on questions relating to 
internal drive, such as: ‘I am interested in having new experiences’. The results of 
the three studies for the late motormanifest HDGECs diverted, although apathetic 
patients in advanced stages with cognitive impairments may be less aware of their 
symptoms. 
One limitation of our study is that we might have a selection bias. We asked all 
possible that more severe apathetic or cognitively impaired participants declined to 
participate in this study. In addition, we assumed that the proxy is the most reliable 
individual to indicate the severity of apathy of the HDGECs. However, the proxy is 
personally involved and might not be able to objectively judge the degree of apathy. 
advanced disease stage, and it provides further evidence that the HDGECs were 
capable of assessing the level of apathy on a self-report questionnaire in the early stage 
of the disease. More precisely, in our study the pre-motormanifest individuals were 
aware of subtle changes which were unnoticed by their proxies. Taken together with 
for exclusion in clinical trials for the assessment of apathy in the pre-motormanifest 
and early manifest disease stages.
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and apathy in Huntington’s disease (HD). This information is particularly useful to 
optimize clinical care and to aid the design of future clinical trials. 
(i.e. pre-motormanifest) or presence (i.e. motormanifest) of motor symptoms. 
useful distinction between HDGECs and whether these groups are homogeneous, 
chapter 
2). When dividing our cohort of 487 HDGECs according to absence and presence 
of motor symptoms, about 20% of the pre-motormanifest individuals were already 
clinically diagnosed based on cognitive and/or psychiatric symptoms. This leads to 
the conclusion that cognitive decline starts before motor symptoms are present and 
that these symptoms are clinically severe enough to diagnose individuals with HD 
without any motor symptoms. This is in line with previous research1-4. These results 
emphasize that the recently published guidelines, which state that HD diagnosis 
can be given purely on cognitive and/or psychiatric symptoms5
In order to understand how this early cognitive decline further develops throughout 
disease progression, we used the entire REGISTRY cohort with the aim of mapping 
chapter 3). We found that 
again leads to the conclusion that cognitive decline is often present before motor 
symptoms are apparent. In our study, tasks measuring psychomotor speed with low 
motor component, i.e. Stroop Word and Color test, were sensitive in detecting early 
cognitive decline, as well as tracking this decline throughout the later stages of the 
disease. Thus, psychomotor tasks are suitable for tracking cognitive abilities over time 
in HD. 
We do not know why cognitive decline starts early in the course of their disease 
total functional capacity and atrophy in the brain6, 7. Therefore, we evaluated whether 
chapter 3). Indeed, our results 
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cognitive performance between HDGECs taking medication targeting non-cognitive 
neuropsychiatric signs and/or tetrabenazine and non-users (chapter 4
we have shown that symptom management is common in HD: about 42% of all 
selective serotonin reuptake inhibitor (SSRI) antidepressants, antipsychotics, 
atypical antipsychotics or tetrabenazine. Medication use gradually increased from 
pre-motormanifest participants (12%) to late stage manifest participants (81%) and 
antipsychotics and tetrabenazine on cognitive performance in the real-life medication 
cognitive performance. Concluding, group analysis did not show medication to have a 
Apathy
The behavioral symptoms in HD are diverse8
behavioral symptom closely related to disease progression9-11 and is present in almost 
all late stage HDGECs11
goal-directed behavior, cognition, and emotion’12 and, in general, is associated with a 
disruption of the prefrontal cortex - basal ganglia circuit13
a relationship between apathy and the neurodegenerative process in HD (chapter 5). 
Our results are in line with previous studies that apathy is common and can already be 
present in the pre-motormanifest stage. In addition, we have shown that that atrophy 
of the thalamus is associated with apathy leading us to conclude that also in HD 
However, no other subcortical structure was found to be associated with apathy. 
Very recently one study found that the prefrontal cortex is associated with apathy in 
HD14
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prefrontal cortex is associated with developing apathy in HD rather than subcortical 
structures. 
Some studies have shown that HDGECs are unaware of their symptoms, including 
their behavioral symptoms15, 16. Therefore, we evaluated whether HDGECs and their 
proxies agree on the degree of apathy by using a self-report questionnaire (chapter 
6
the incident and severity rate drastically increase from the early HD stage to the late 
motormanifest stages. Overall, proxies and HDGECs agree on the degree of apathy. 
In the pre-motormanifest stage HDGECs even report more apathy than their proxies, 
although the overall degree of apathy is generally low in this stage. However, it could 
be the case that pre-motormanifest HDGECs are more aware of internal changes than 
their proxies. 
Concluding remarks
Over the recent years a unique situation has arisen for HDGECs, as several clinical 
trials were set up to evaluate medication for symptomatic treatment17. Very recently, 
one trial has been launched which aims to lower the huntingtin level in the brain to 
stop or delay the neurogenerative process18. Many trials have been set up and there are 
at the horizon. With the results of our work we can advise to include executive function 
moment, no threshold is known at which to conclude that cognitive impairment (due 
to HD) has started. When it comes to evaluating cognition, we would favor to group 
motor symptoms. In addition, we have shown that medication targeting non-cognitive 
neuropsychiatric disturbances and tetrabenazine might not have such an enormous 
think that exclusion criteria based on medication use should be carefully evaluated, 
as in group analysis the individual usage of certain medication might not make much 
which should be carefully evaluated and if necessary be replace by other medication. 
Considering that executive dysfunction and apathy seem to be closely related, 
we would advise to also evaluate apathy in a standardized way when cognition is 
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The HD community hopes that an intervention which slows or stops the disease 
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Nederlandse Samenvatting
Het hoofddoel van dit proefschrift was om meer kennis over het beloop van cognitie 
en apathie bij de ziekte van Huntington (ZvH) te krijgen. Deze informatie is belangrijk 
om de zorg te kunnen optimaliseren en om te kunnen adviseren hoe een klinische 
studie opgezet moet worden. 
Cognitie
In de wetenschap is het gebruikelijke dat ZvH gendragers ingedeeld worden op 
basis van afwezigheid (pre-motormanifest) en aanwezigheid (motormanifest) van 
motorische symptomen. Daarom hebben we eerst uitgezocht of deze gebruikelijke 
van de deelnemerskarakteristieken aan het grootste Europese REGISTRY-
hoofdstuk 2). 
af- of aanwezigheid van motorische symptomen, waarbij ongeveer 20% van de pre-
motormanifeste individuen al klinisch met HD gediagnosticeerd waren op grond van 
evidente cognitieve en/of psychiatrische symptomen.  Dit leidt tot de conclusie dat 
cognitieve achteruitgang begint voordat motorische symptomen aanwezig zijn en dat 
deze symptomen klinisch ernstig genoeg waren om de ZvH diagnose te stellen zonder 
enige motorische symptomen, wat in lijn is met eerder onderzoek. Deze resultaten 
bevestigen de behoefte aan de onlangs gepubliceerde richtlijn waarin is vastgelegd 
dat de ZvH diagnose op grond van alleen cognitieve en/of psychiatrische symptomen 
gesteld kan en mag worden. Om te begrijpen hoe deze vroege cognitieve achteruitgang 
zich gedurende het ziekteproces verder ontwikkelt, hebben we het volledige 
kaart te brengen (hoofdstuk 3). We vonden dat in de pre-motormanifeste stadia er 
dat cognitieve achteruitgang vaak al voor de motorische symptomen aanwezig is. 
In onze studie bleken taken die de psychomotorische snelheid meten met een lage 
detecteren van vroege cognitieve achteruitgang en deze cognitieve achteruitgang ook 
in de late stadia te kunnen blijven volgen. Psychomotorische taken zijn uitermate 
geschikt om de cognitieve vaardigheden in de loop van de tijd te volgen bij de ZvH. 
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We kunnen niet verklaren waarom bij sommige ZvH gendragers de cognitieve 
achteruitgang sneller verloopt dan bij anderen. Over het algemeen weten we dat de 
(hoofdstuk 3
lengte een snellere cognitieve achteruitgang laten zien. Dit is niet verrassend omdat 
cognitieve tekorten worden geassocieerd met veranderingen in de hersenen en dit 
kunnen ook andere factoren, zoals medicatiegebruik, zijn die de cognitieve prestaties 
beïnvloeden. Omdat geen genezing voor de ZvH beschikbaar is, gebruiken veel ZvH 
gendragers medicatie om de symptomen te bestrijden. Daarom hebben we onderzocht 
of er verschil bestaat in cognitieve prestaties tussen ZvH gendragers die medicatie 
gericht op niet-cognitieve neuropsychiatrische symptomen en/of tetrabenazine 
gebruiken en niet-gebruikers (hoofdstuk 4). Ten eerste hebben we aangetoond dat 
symptoombehandeling gebruikelijk is bij de ZvH: ongeveer 42% van alle REGISTRY-
serotonineheropnameremmer (SSRI) antidepressiva, antipsychotica, atypische 
antipsychotica of tetrabenazine. Het medicatiegebruik steeg geleidelijk van pre-
motormanifeste deelnemers (12%) naar laatstadium manifest deelnemers (81%); ook 
het tegelijktijdig gebruik van meerdere medicijnen, polyfarmacie, steeg van 3% naar 
cognitieve prestaties in de vroege ZvH stadia; dat willen zeggen dat deelnemers die 
antipsychotica gebruikten slechter presteerden op de cognitieve taken. We hebben 
de cognitieve prestaties gevonden, het betreft hierbij het gebruik van medicatie zoals 
we dat in de dagelijkse praktijk zien, niet aangepast voor deze studie. Een belangrijke 
medicatie gebruik is gekeken. Concluderend, in groepsanalyse lijkt medicatie geen 
in de vroege ZvH stadia. 
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Apathie 
en is het enige gedragssymptoom dat nauw verband houdt met ziekteprogressie en 
emotie” en wordt in het algemeen geassocieerd met een verstoring van het prefrontale 
apathie en het neurodegeneratieve proces bestaat bij de ZvH (hoofdstuk 5). Onze 
resultaten zijn in overeenstemming met eerdere studies: apathie komt veel voor en kan 
apathie bij de ZvH ook geassocieerd wordt met een verstoring van het prefrontale 
en de prefrontale cortex bij de ZvH gevonden. Dit pleit er wederom voor dat het 
prefrontale cortex - basal ganglia circuit betrokken is, maar dan vooral de prefrontale 
cortex en niet de subcorticale structuren.
Sommige studies hebben aangetoond dat ZvH gendragers zich niet bewust zijn van 
hun symptomen, inclusief hun eigen gedrag. Daarom evalueerden we of ZvH gendragers 
en hun partners het eens zijn over de mate van apathie bij de ZvH gendrager door 
een zelfrapportagevragenlijst te gebruiken (hoofdstuk 6). Zoals eerder vermeld kan 
apathie reeds aanwezig zijn in een laag aantal pre-motormanifest individuen, maar 
neemt de frequentie en mate van apathie drastisch toe van de vroege motormanifest 
fase naar de late motormanifest stadia. Over het algemeen zijn partners en ZvH 
gendragers het eens over de mate van apathie. In het pre-motormanifeste stadium 
melden ZvH gendragers zelfs meer apathie dan hun partners/mantelzorgers, hoewel 
de mate van apathie over het algemeen laag is in deze fase. Dit doet vermoeden dat 
pre-motormanifeste ZvH gendragers zich meer bewust zijn van interne veranderingen 
dan hun mantelzorgers. 
Slotopmerkingen
De afgelopen jaren is er een unieke situatie voor ZvH gendragers ontstaan omdat 
behandeling te evalueren. In 2019 zal een studie starten met als doel het 
huntingtine niveau in de hersenen te verlagen en op deze manier te bezien of het 
neurodegeneratieve proces te vertragen of te stoppen is. Er zijn inmiddels veel studies 
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zien. Met de resultaten van onze studies pleiten wij ervoor dat executieve functies in 
het onderzoeksprotocol opgenomen moeten worden als de cognitie getest wordt, met 
nadruk op psychomotorische snelheid. Toch is er nog geen drempelwaarde bekend 
waarbij geconcludeerd mag worden dat er cognitieve stoornissen veroorzaakt door de 
neuropsychiatrische stoornissen en tetrabenazine mogelijk niet een zo grote invloed 
heeft op de cognitieve uitkomst op groepsniveaus als eerder werd aangenomen. We 
denken dat exclusiecriteria op basis van medicatiegebruik zorgvuldig moeten worden 
geëvalueerd, omdat het aannemelijk is dat er in de groepsanalyse weinig invloed is 
van medicatie gebruik. Uiteraard kunnen deze medicijnen wel op individuele basis 
Gezien het feit dat executieve dysfunctie en apathie nauw samengaan, adviseren 
we om apathie op een gestandaardiseerde manier te evalueren in alle gevallen dat 
er cognitie wordt gemeten in een klinische studie. Zeker wanneer verwacht wordt 
beïnvloed kan worden. 
De ZvH gemeenschap hoopt dat een interventie die het ziekteproces vertraagt of 
stopt snel zal worden gevonden. Onze resultaten dragen bij om deze klinische studies 
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